Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LW231 in chronic hepatitis B virus infection
CTR20253911Phase 2Active
- Sponsor
- Shanghai Changsen Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LW231 in Chronic Hepatitis B (CHB), sponsored by Shanghai Changsen Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
LW231
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20253911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253911.